MeSH term
Frequency | Condition_Probility | Adult | 13 | 0.0 |
Albuterol/administration & dosage/*pharmacokinetics/urine | 2 | 100.0 |
Biological Availability | 2 | 0.0 |
Bronchodilator Agents/administration & dosage/*pharmacokinetics/urine | 2 | 100.0 |
Comparative Study | 15 | 0.0 |
Female | 21 | 0.0 |
Humans | 54 | 0.0 |
Lung/*metabolism | 3 | 3.0 |
Male | 19 | 0.0 |
*Nebulizers and Vaporizers | 5 | 25.0 |
Models, Biological | 3 | 0.0 |
Animals | 19 | 0.0 |
Dose-Response Relationship, Drug | 3 | 0.0 |
Hamsters | 5 | 0.0 |
Immunohistochemistry | 10 | 0.0 |
In Situ Hybridization | 2 | 0.0 |
Mice | 3 | 0.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Rabbits | 7 | 0.0 |
Research Support, Non-U.S. Gov't | 34 | 0.0 |
In Vitro | 2 | 0.0 |
Middle Aged | 7 | 0.0 |
Adolescent | 6 | 0.0 |
Biopsy | 3 | 0.0 |
Child | 4 | 0.0 |
Child, Preschool | 5 | 0.0 |
DNA Mutational Analysis | 3 | 0.0 |
Infant | 9 | 0.0 |
Magnetic Resonance Imaging | 2 | 0.0 |
Microscopy, Electron | 6 | 0.0 |
Phenotype | 3 | 0.0 |
Energy Metabolism | 2 | 1.0 |
*Exercise | 2 | 1.0 |
Time Factors | 2 | 0.0 |
Adrenergic beta-Agonists/*administration & dosage | 2 | 22.0 |
Albuterol/*administration & dosage | 3 | 100.0 |
Infant, Newborn | 7 | 0.0 |
Treatment Outcome | 3 | 0.0 |
Signal Transduction | 2 | 0.0 |
Administration, Inhalation | 8 | 4.0 |
Analysis of Variance | 3 | 0.0 |
Bronchodilator Agents/*administration & dosage | 4 | 66.0 |
Cross-Over Studies | 4 | 0.0 |
Double-Blind Method | 4 | 0.0 |
Prospective Studies | 2 | 0.0 |
Respiration, Artificial | 2 | 3.0 |
Aged | 7 | 0.0 |
Aerosols | 4 | 5.0 |
Nebulizers and Vaporizers | 5 | 29.0 |
*Respiration, Artificial | 2 | 20.0 |
Single-Blind Method | 2 | 0.0 |
Bombesin/*analysis | 2 | 100.0 |
Albuterol/*administration & dosage/therapeutic use | 2 | 100.0 |
Costs and Cost Analysis | 2 | 3.0 |
*Intubation, Intratracheal | 2 | 28.0 |
Bombesin/analysis | 5 | 27.0 |
Calcitonin/analysis | 4 | 16.0 |
Calcitonin Gene-Related Peptide/analysis | 2 | 2.0 |
Microscopy, Immunoelectron | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 8 | 0.0 |
Chromosome Mapping | 2 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Muscle Proteins/*genetics | 4 | 2.0 |
Neurosecretory Systems/pathology | 2 | 18.0 |
Animals, Newborn | 3 | 0.0 |
Chemoreceptors/*physiology | 2 | 50.0 |
Fetus | 5 | 0.0 |
Tumor Cells, Cultured | 2 | 0.0 |
*Chromosome Mapping | 2 | 0.0 |
Rats | 6 | 0.0 |
Acute Disease | 2 | 0.0 |
Lung Diseases, Obstructive/*drug therapy | 2 | 66.0 |
Antibody Specificity | 2 | 0.0 |
Bronchi/cytology | 2 | 7.0 |
Epithelial Cells | 6 | 1.0 |
Nerve Tissue Proteins/*analysis | 2 | 2.0 |
Neurosecretory Systems/*cytology | 3 | 27.0 |
Sensitivity and Specificity | 2 | 0.0 |
Serotonin/*analysis | 2 | 20.0 |
Base Sequence | 2 | 0.0 |
Hyperplasia | 2 | 0.0 |
Staining and Labeling | 3 | 0.0 |
English Abstract | 6 | 0.0 |
*Mutation | 2 | 0.0 |
Lung/*cytology/embryology | 2 | 50.0 |
Biological Markers | 2 | 0.0 |
Chromogranins/metabolism | 2 | 6.0 |
Pregnancy | 2 | 0.0 |
Serotonin/analysis | 2 | 8.0 |
Haplorhini | 2 | 0.0 |
Immunoenzyme Techniques | 2 | 0.0 |
Swine | 2 | 0.0 |
Microscopy, Electron, Scanning | 2 | 0.0 |
Histocytochemistry | 3 | 0.0 |
Enkephalin, Leucine/analysis | 2 | 40.0 |
